Filing Flows › Halozyme Therapeutics (HALO) › Net income
Halozyme Therapeutics (HALO) net income by quarter
Halozyme Therapeutics' net income was $247M in Q3 2026 (third quarter 2026), +7% from Q2 2026. Over the last 6 quarters it ranged from $118M (Q1 2025) to $247M (Q3 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $247M | +7% | +41% |
| Q2 2026 | $230M | +53% | +39% |
| Q1 2026 | $150M | -14% | +27% |
| Q3 2025 | $175M | +6% | — |
| Q2 2025 | $165M | +40% | — |
| Q1 2025 | $118M | — | — |
Q3 2026 at a glance
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Questions
What is Halozyme Therapeutics' net income?
Halozyme Therapeutics' net income was $247M in Q3 2026 (third quarter 2026), +7% from Q2 2026.
How has Halozyme Therapeutics' net income changed?
Over the last 6 quarters it ranged from $118M (Q1 2025) to $247M (Q3 2026).